Oncotype Dx Breast Recurrence Score® Test
Overview
Oncotype Dx Breast Recurrence Score® Test is a biotechnology company headquartered in Amsterdam, Netherlands, with approximately 5,001 employees.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Oncotype Dx Breast Recurrence Score® Test in our records. PharmaTek screens the full directory against live FDA enforcement data.
Related companies
Ace Pharmaceuticals B.V.
Netherlands
Amsterdam UMC
Netherlands
Amsterdam University Medical Centers
Netherlands
Amsterdam University Medical Centers, Location VUmc
Netherlands
Barentz International B.V.
Netherlands
Centrafarm Services B.V.
Netherlands
Maastricht University Medical Center+
Netherlands
Merus N.V.
Netherlands
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.